Late na(+) current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model.

J Am Coll Cardiol

Department of Medical Physiology, Division of Heart and Lungs, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands.

Published: February 2010

Objectives: This study investigated whether ranolazine reduces dofetilide-induced torsades de pointes (TdP) in a model of long QT syndrome with down-regulated K(+) currents due to hypertrophic remodeling in the dog with chronic atrioventricular block (cAVB).

Background: Ranolazine inhibits the late Na(+) current (I(NaL)) and is effective against arrhythmias in long QT3 syndromes despite its blocking properties of the rapid component of delayed rectifying potassium current.

Methods: Ranolazine was administered to cAVB dogs before or after TdP induction with dofetilide and electrophysiological parameters were determined including beat-to-beat variability of repolarization (BVR). In single ventricular myocytes, effects of ranolazine were studied on I(NaL), action potential duration, and dofetilide-induced BVR and early afterdepolarizations.

Results: After dofetilide, ranolazine reduced the number of TdP episodes from 10 +/- 3 to 3 +/- 1 (p < 0.05) and partially reversed the increase of BVR with no abbreviation of the dofetilide-induced QT prolongation. Likewise, pre-treatment with ranolazine, or using lidocaine as a specific Na(+) channel blocker, attenuated TdP, but failed to prevent dofetilide-induced increases in QT, BVR, and ectopic activity. In cAVB myocytes, ranolazine suppressed dofetilide-induced early afterdepolarizations in 25% of cells at 5 micromol/l, in 75% at 10 micromol/l, and in 100% at 15 micromol/l. At 5 micromol/l, ranolazine blocked 26 +/- 3% of tetrodotoxin-sensitive I(NaL), and 49 +/- 3% at 15 micromol/l. Despite a 54% reduction of I(NaL) amplitude in cAVB compared with control cells, I(NaL) inhibition by 5 micromol/l tetrodotoxin equally shortened relative action potential duration and completely abolished dofetilide-induced early afterdepolarizations.

Conclusions: Despite down-regulation of I(NaL) in remodeled cAVB hearts, ranolazine is antiarrhythmic against drug-induced TdP. The antiarrhythmic effects are reflected in concomitant changes of BVR.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2009.10.033DOI Listing

Publication Analysis

Top Keywords

ranolazine
10
late na+
8
na+ current
8
ranolazine reduces
8
torsades pointes
8
chronic atrioventricular
8
atrioventricular block
8
action potential
8
potential duration
8
dofetilide-induced early
8

Similar Publications

Effect of electrochemical topology on detection sensitivity in MEA assay for drug-induced cardiotoxicity screening.

Biosens Bioelectron

December 2024

Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21205, United States; Department of Medicine, Johns Hopkins University, Baltimore, MD, 21205, United States; Institute for NanoBio Technology, Johns Hopkins University, Baltimore, MD, 21218, United States; Center for Microphysiological Systems, Johns Hopkins University, Baltimore, MD, 21205, United States. Electronic address:

Cardiotoxicity remains a major challenge in drug development, accounting for 45% of medication withdrawals due to cardiac ischemia and arrhythmogenicity. To overcome the limitations of traditional multielectrode array (MEA)-based cardiotoxicity assays, we developed a Nafion-coated NanoMEA platform with decoupled reference electrodes, offering enhanced sensitivity for electrophysiological measurements. The 'Decoupled' configuration significantly reduced polarization resistance (Rp) from 12.

View Article and Find Full Text PDF

Background: Microvascular angina (MVA) is an important contributor to morbidity and mortality in patients with non-obstructive coronary artery disease. Despite improvements in its recognition and diagnosis, uncertainty remains around the most effective treatment strategy, and more data are needed.

Aims: We aimed to evaluate the quality of patient selection in treatment studies of MVA and provide a contemporary overview of the evidence base for the treatment of MVA.

View Article and Find Full Text PDF

Background: Myocardial infarction with no obstructive coronary arteries (MINOCA), and ischemia with no obstructive coronary arteries (INOCA), are female-predominant conditions; clinical trials are lacking to guide medical management for the common underlying vasomotor etiologies. Data on long-term outcomes of (M)INOCA patients following attendance at a women's heart centre (WHC) are lacking.

Methods: Women diagnosed with MINOCA (n = 51) or INOCA (n = 112) were prospectively followed for 3 years at the Leslie Diamond WHC (LDWHC) in Vancouver.

View Article and Find Full Text PDF

Tomatidine, a major tomato glycoalkaloid, is effective for the prevention of skeletal muscle wasting and enhancing mitophagy. However, its effects on transmembrane ionic currents are not well explored. In this study, we explored the interactions between tomatidine and Na+ current.

View Article and Find Full Text PDF

Stable Angina Pectoris: A Review of Pathophysiology, Diagnosis, and Its Management.

J Assoc Physicians India

November 2024

Director, Department of Medical Affairs, Dr Reddy's Laboratories Ltd., Ameerpet, Hyderabad, Telangana, India.

Article Synopsis
  • India faces a growing epidemic of cardiovascular diseases, particularly coronary artery disease, due to rapid urbanization and globalization, with over 7 million deaths annually from CAD.
  • Key challenges in low- and middle-income countries include a lack of awareness about risk factors, healthcare access, and affordability of treatment.
  • Effective management of angina pectoris involves collaboration among patients and healthcare providers and utilizes both first-line (like CCBs and β-blockers) and second-line antianginal medications to improve patient outcomes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!